AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the
Exchange Act of 1934
of Report (Date of earliest event reported): July 8, 2020
name of registrant as specified in its charter)
|(State or other jurisdiction
Hayden Avenue, Suite 390
|(Address of principal
executive offices) (Zip Code)|
telephone number, including area code)
name or former address, if changed since last report)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))|
registered pursuant to Section 12(b) of the Act:
of each class
of exchange on which registered|
|Common Stock, par
value $0.0001 per share
||The NASDAQ Stock
Market LLC |
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company [ ]
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
7.01. Regulation FD Disclosure.
July 8, 2020, Pulmatrix, Inc. (the “Company”) issued a press release announcing that Sensory Cloud, Inc., which licensed
the rights to the Company’s NasoCalm proprietary formulations (PUR003 and PUR006), plans to commence commercial sales of
FEND in September 2020. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set
forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form
8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits
hereto, is material or that the dissemination of such information is required by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
July 8, 2020